These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2068465)

  • 1. Safety of aztreonam in patients with cystic fibrosis and allergy to beta-lactam antibiotics.
    Jensen T; Pedersen SS; Høiby N; Koch C
    Rev Infect Dis; 1991; 13 Suppl 7():S594-7. PubMed ID: 2068465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses.
    Koch C; Hjelt K; Pedersen SS; Jensen ET; Jensen T; Lanng S; Valerius NH; Pedersen M; Høiby N
    Rev Infect Dis; 1991; 13 Suppl 7():S608-11. PubMed ID: 2068467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics.
    Moss RB; McClelland E; Williams RR; Hilman BC; Rubio T; Adkinson NF
    Rev Infect Dis; 1991; 13 Suppl 7():S598-607. PubMed ID: 2068466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
    Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam for cystic fibrosis patients who are hypersensitive to other beta-lactams.
    Jensen T; Koch C; Pedersen SS; Høiby N
    Lancet; 1987 Jun; 1(8545):1319-20. PubMed ID: 2884440
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG
    Pediatr Infect Dis J; 1988 Mar; 7(3):171-6. PubMed ID: 3128767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach.
    Guglani L; Abdulhamid I; Ditouras J; Montejo J
    Ann Pharmacother; 2012 Oct; 46(10):e25. PubMed ID: 23012384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled aztreonam.
    O'Sullivan BP; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 May; 9(5):357-8. PubMed ID: 20431562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Scully BE; Ores CN; Prince AS; Neu HC
    Rev Infect Dis; 1985; 7 Suppl 4():S669-74. PubMed ID: 3909322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation.
    Schechter MS; Trueman D; Farquharson R; Higuchi K; Daines CL
    Ann Am Thorac Soc; 2015 Jul; 12(7):1030-8. PubMed ID: 26053185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
    Allen JE; Bosso JA; Saxon BA; Matsen JM
    Diagn Microbiol Infect Dis; 1987 Sep; 8(1):51-5. PubMed ID: 3126018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of nebulised aztreonam lysine (AZLI) in aztreonam hypersensitive patients.
    Whitaker P; Etherington C; Williams K; Conway S; Peckham D
    J Cyst Fibros; 2012 Jul; 11(4):353. PubMed ID: 22341263
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of aztreonam in the cystic fibrosis patient.
    Matsen JM; Bosso JA
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S117-9; discussion S128-32. PubMed ID: 2682510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.